Executive Summary of Evidence-Based Guidelines for the Diagnosis and Treatment of Pediatric CKD-Mineral and Bone Disorder (Version 2024).

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in children refers to the systemic mineral and bone metabolism disorders caused by CKD, including biochemical abnormalities, abnormalities in bone turnover, mineralization, quality, and ectopic calcification. Like adult patients, mineral metabolism and bone structure abnormalities are universally present in children with CKD. However, there have been no guidelines specifically for children in the past. The medication treatment and clinical practices for children are usually based on those for adults, thus lacking targeted guidance. Children are in the process of growth and development, and adult guidelines do not take into account the characteristics of children. In addition, the medication range for children is different from that of adults, and new drugs have been verified and tested in children. Therefore, based on the developmental characteristics of children, combined with expert opinions about adults, children, kidney, nutrition, and medicine, this guideline was initiated by the Subspecialty Group of Nephrology, the Society of Pediatrics, Chinese Medical Association. It answers many important clinical questions related to the diagnosis and treatment of pediatric CKD-MBD, aims to provide individualized treatment plans considering the clinical characteristics of children with CKD and their treatment goals, while addressing the needs of their growth and development.